[go: up one dir, main page]

PE20181517A1 - Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer - Google Patents

Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer

Info

Publication number
PE20181517A1
PE20181517A1 PE2018001375A PE2018001375A PE20181517A1 PE 20181517 A1 PE20181517 A1 PE 20181517A1 PE 2018001375 A PE2018001375 A PE 2018001375A PE 2018001375 A PE2018001375 A PE 2018001375A PE 20181517 A1 PE20181517 A1 PE 20181517A1
Authority
PE
Peru
Prior art keywords
peptide
cancers
supports
various types
peptide combinations
Prior art date
Application number
PE2018001375A
Other languages
English (en)
Inventor
Andrea Mahr
Toni Weinschenk
Oliver Schoor
Jens Fritsche
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PE20181517A1 publication Critical patent/PE20181517A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Se refiere a un peptido que comprende una secuencia de aminoacidos seleccionada de la SEQ ID NO 323, y secuencias variantes de las mismas que son como minimo homologas en un 88% a la SEQ ID NO 323, y en que dicha variante se une a una o varias moleculas del complejo mayor de histocompatibilidad (MHC) y/o induce la reaccion cruzada de linfocitos T con dicho peptido variante; y una sal farmaceuticamente aceptable del mismo, en que dicho peptido no es un polipeptido entero. Tambien se refiere a un metodo para producir el peptido y una composicion farmaceutica. La presente invencion es util para el tratamiento de enfermedades proliferativas tales como glioblastoma, cancer de mama, cancer colorrectal, entre otros.
PE2018001375A 2015-08-28 2016-08-26 Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer PE20181517A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562211276P 2015-08-28 2015-08-28
GBGB1515321.6A GB201515321D0 (en) 2015-08-28 2015-08-28 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

Publications (1)

Publication Number Publication Date
PE20181517A1 true PE20181517A1 (es) 2018-09-21

Family

ID=54326487

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2018001375A PE20181517A1 (es) 2015-08-28 2016-08-26 Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer
PE2018000318A PE20181164A1 (es) 2015-08-28 2016-08-26 Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2018000318A PE20181164A1 (es) 2015-08-28 2016-08-26 Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer

Country Status (18)

Country Link
US (7) US10525114B2 (es)
EP (2) EP3461494A1 (es)
JP (2) JP6970974B2 (es)
KR (3) KR20180038550A (es)
CN (1) CN107921111B (es)
AU (3) AU2016313684B2 (es)
BR (1) BR112018003460A2 (es)
CA (2) CA2996963A1 (es)
CR (6) CR20200492A (es)
EA (2) EA201890560A1 (es)
GB (1) GB201515321D0 (es)
MA (7) MA43461B1 (es)
MX (1) MX2018002480A (es)
PE (2) PE20181517A1 (es)
SG (3) SG10202001830PA (es)
TW (15) TWI722656B (es)
UA (1) UA124577C2 (es)
WO (1) WO2017036936A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TWI765875B (zh) 2015-12-16 2022-06-01 美商磨石生物公司 新抗原辨識、製造及用途
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CN108250286B (zh) * 2016-12-28 2021-06-08 香雪生命科学技术（广东）有限公司 源自于pasd1的肿瘤抗原短肽
JP7026970B2 (ja) 2017-04-10 2022-03-01 イマティクス バイオテクノロジーズ ゲーエムベーハー 白血病およびその他のがんに対する免疫療法において使用するためのペプチドおよびペプチドの組み合わせ
US10899819B2 (en) 2017-04-10 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
ES2898210T3 (es) 2017-07-14 2022-03-04 Immatics Biotechnologies Gmbh Molécula de polipéptido con especificidad dual mejorada
HUE061502T2 (hu) * 2017-09-28 2023-07-28 Immpact Bio Ltd Univerzális platform gátló kiméra antigén receptor (ICAR) elõállítására
EP3694532B1 (en) 2017-10-10 2025-02-26 Gritstone bio, Inc. Neoantigen identification using hotspots
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
DE102018107224A1 (de) * 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
CN109467596B (zh) * 2018-11-12 2021-11-09 湖北省农业科学院畜牧兽医研究所 转录因子sp1在调控猪rtl1基因表达中的应用
CN109738929B (zh) * 2018-12-03 2022-10-21 中国辐射防护研究院 一种基于居民食物最大消费量的剂量估算方法及系统
TWI858016B (zh) * 2019-02-18 2024-10-11 日商肽夢想股份有限公司 血球凝集素結合肽
EP3970739A1 (en) * 2019-05-13 2022-03-23 Itoh, Kyogo Method for determining eligibility of cancer patients for peptide vaccine therapy
CN110123453B (zh) * 2019-05-31 2021-07-23 东北大学 一种基于无标记增强现实的手术导航系统
WO2021207826A1 (en) * 2020-04-14 2021-10-21 Université de Montréal Novel tumor-specific antigens for acute lymphoblastic leukemia (all) and uses thereof
CN111910000B (zh) * 2020-07-02 2022-07-01 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种预测鼻咽癌预后的肿瘤微环境成分标志物组合及系统
EP4326306A4 (en) * 2021-04-19 2025-10-08 Univ Texas METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES
CN115607573B (zh) * 2022-12-16 2023-05-23 北京大学第三医院（北京大学第三临床医学院） 一种用于调节杀伤性t细胞活性的方法、药物及其应用
WO2025015234A2 (en) * 2023-07-13 2025-01-16 Ltz Therapeutics Inc. Multispecific antibodies and uses thereof
CN118834328B (zh) * 2024-07-02 2025-09-16 江苏海洋大学 金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用
CN120183512B (zh) * 2025-05-23 2025-08-12 浙江省肿瘤医院 基于转录组测序构建的用于诊断早期宫颈癌淋巴结转移的方法、模型

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832125A4 (en) * 1995-06-05 1998-12-30 Human Genome Sciences Inc HUMAN G PROTEIN RECEPTOR HGBER32
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses
US7342108B2 (en) * 1998-06-25 2008-03-11 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
JP4315301B2 (ja) 1998-10-30 2009-08-19 独立行政法人科学技術振興機構 ヒトＨ３７タンパク質と、このタンパク質をコードする ｃＤＮＡ
US6680197B2 (en) * 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
GB0119473D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Compounds
US6953672B2 (en) * 2001-08-21 2005-10-11 Millennium Pharmaceuticals, Inc. Screen for CDC7 inhibitors
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
BRPI0410343A (pt) * 2003-05-05 2006-05-30 Pharmacia Italia Spa formas truncadas de dbf4 humana, complexos com seus pares de interação e métodos para identificação de seus inibidores
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
WO2005073374A1 (ja) * 2004-01-29 2005-08-11 Dainippon Sumitomo Pharma Co., Ltd. 新規腫瘍抗原蛋白質及びその利用
JP5354680B2 (ja) * 2007-07-10 2013-11-27 塩野義製薬株式会社 Ｍｍｐ１３に対する中和活性を有するモノクローナル抗体
NZ582824A (en) * 2007-07-27 2012-07-27 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumors
ES2689851T3 (es) * 2007-07-27 2018-11-16 Immatics Biotechnologies Gmbh Nuevos epítopos inmunogénicos para inmunoterapia
DK2220245T3 (en) * 2007-10-17 2015-06-29 Univ Leland Stanford Junior Method and composition for the crystallization of G protein coupled receptors
CN102165688A (zh) 2008-03-31 2011-08-24 新加坡科技研究局 高效率线性发射器
TW201000115A (en) * 2008-06-11 2010-01-01 Oncotherapy Science Inc IQGAP3 epitope peptides and vaccines containing the same
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
SI2172211T1 (sl) 2008-10-01 2015-03-31 Immatics Biotechnologies Gmbh Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka
ITBO20090075A1 (it) * 2009-02-13 2010-08-14 Magneti Marelli Spa Macchina elettrica con singolo statore e due rotori tra loro indipendenti e veicolo stradale provvisto di tale macchina elettrica
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012048291A2 (en) * 2010-10-08 2012-04-12 Proteapex Therapeutics Llc Compositions and methods for inhibition of mmp:mmp-substrate interactions
CN103458930B (zh) * 2011-02-01 2019-10-15 健玛保 针对cd74的人抗体和抗体-药物缀合物
CN104081202A (zh) 2011-09-12 2014-10-01 克里蒂科斯有限责任公司 检测靶分子的非侵入性方法
WO2013070603A1 (en) 2011-11-11 2013-05-16 Cedars-Sinai Medical Center Compositions and methods for treatment of kidney diseases
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US10501512B2 (en) * 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
JP2015528443A (ja) 2012-08-15 2015-09-28 ユニヴェルシテ・ドゥ・モントリオール 新規マイナー組織適合抗原を同定するための方法
JP6461796B2 (ja) * 2012-09-14 2019-01-30 アメリカ合衆国 Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体
WO2014160275A2 (en) 2013-03-14 2014-10-02 Battell Memorial Institute Biomarkers for liver fibrosis
TWI777194B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
WO2015092710A1 (en) * 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017184590A1 (en) * 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods

Also Published As

Publication number Publication date
CN107921111A (zh) 2018-04-17
PE20181164A1 (es) 2018-07-19
SG10202001830PA (en) 2020-04-29
TW202024112A (zh) 2020-07-01
JP6970974B2 (ja) 2021-11-24
US20200054729A1 (en) 2020-02-20
CA3072922A1 (en) 2017-03-09
MA43461B1 (fr) 2021-03-31
US20200397879A1 (en) 2020-12-24
TWI722660B (zh) 2021-03-21
TWI782290B (zh) 2022-11-01
TWI722655B (zh) 2021-03-21
CN107921111B (zh) 2022-07-26
TW201920233A (zh) 2019-06-01
GB201515321D0 (en) 2015-10-14
AU2018250464A1 (en) 2018-11-15
US10898557B2 (en) 2021-01-26
KR20210122894A (ko) 2021-10-12
MA42694A (fr) 2018-07-04
US10695411B2 (en) 2020-06-30
US20200061170A1 (en) 2020-02-27
TW202021613A (zh) 2020-06-16
US20200323968A1 (en) 2020-10-15
CR20200494A (es) 2020-11-24
TWI722663B (zh) 2021-03-21
CR20200492A (es) 2020-11-24
TWI699377B (zh) 2020-07-21
TWI722659B (zh) 2021-03-21
CR20180174A (es) 2018-06-06
AU2016313684A1 (en) 2018-04-12
TW202023607A (zh) 2020-07-01
MA43461A1 (fr) 2019-08-30
TW202024111A (zh) 2020-07-01
UA124577C2 (uk) 2021-10-13
EP3461494A1 (en) 2019-04-03
US10568950B1 (en) 2020-02-25
KR20180093123A (ko) 2018-08-20
JP2018532382A (ja) 2018-11-08
SG10202001831SA (en) 2020-04-29
CR20200493A (es) 2020-11-24
MA43459A1 (fr) 2019-08-30
TW202024115A (zh) 2020-07-01
TW202024109A (zh) 2020-07-01
TW202024113A (zh) 2020-07-01
MA43460A1 (fr) 2019-08-30
KR102308798B1 (ko) 2021-10-05
JP7506026B2 (ja) 2024-06-25
EP3341014A1 (en) 2018-07-04
TW201708246A (zh) 2017-03-01
TWI722657B (zh) 2021-03-21
CR20180423A (es) 2018-11-19
US20180250374A1 (en) 2018-09-06
TW202023608A (zh) 2020-07-01
TW202041233A (zh) 2020-11-16
TWI722654B (zh) 2021-03-21
TWI722662B (zh) 2021-03-21
TWI722653B (zh) 2021-03-21
TW202024110A (zh) 2020-07-01
TWI722664B (zh) 2021-03-21
AU2016313684B2 (en) 2020-04-02
US11065316B2 (en) 2021-07-20
AU2018250464B2 (en) 2020-04-09
TWI722661B (zh) 2021-03-21
US20180250373A1 (en) 2018-09-06
AU2020201896B2 (en) 2022-08-25
TW202024127A (zh) 2020-07-01
SG10201807588TA (en) 2018-10-30
MX2018002480A (es) 2018-08-24
TWI722658B (zh) 2021-03-21
WO2017036936A1 (en) 2017-03-09
TW202024114A (zh) 2020-07-01
CR20200495A (es) 2020-11-24
EA201891874A3 (ru) 2019-05-31
MA43457A1 (fr) 2019-08-30
US20200289631A1 (en) 2020-09-17
KR102515909B1 (ko) 2023-03-29
BR112018003460A2 (pt) 2018-09-25
JP2021118721A (ja) 2021-08-12
MA45073A (fr) 2019-04-03
TWI722656B (zh) 2021-03-21
US10898558B2 (en) 2021-01-26
CA2996963A1 (en) 2017-03-09
US10525114B2 (en) 2020-01-07
TW202024126A (zh) 2020-07-01
US10576132B2 (en) 2020-03-03
EA201890560A1 (ru) 2018-08-31
AU2020201896A1 (en) 2020-04-02
EA201891874A2 (ru) 2019-01-31
MA43458A1 (fr) 2019-08-30
KR20180038550A (ko) 2018-04-16

Similar Documents

Publication Publication Date Title
PE20181517A1 (es) Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer
PE20181316A1 (es) Nuevos peptidos y combinacion de peptidos para el uso en la inmunoterapia contra varios tipos de cancer
PE20171442A1 (es) Peptidos y combinacion de peptidos novedosos para su uso en inmunoterapia contra diversos tumores
PE20191248A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
PE20170940A1 (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer
PE20230321A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
PE20171515A1 (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer
PE20180253A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer
PE20180487A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cancer
PE20231014A1 (es) Nuevos peptidos y combinacion de peptidos para usar en inmunoterapia contra el cancer esofagico y otros canceres
PE20180505A1 (es) Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres
PE20211300A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
CR20190095A (es) Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos
PE20171765A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon amicrocitico y otros tipos de cancer
EA201690868A1 (ru) Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга
PE20181897A1 (es) Inmunoterapia contra el melanoma y otros tipos de cancer
EA202090751A3 (ru) Новый метод иммунотерапии нескольких видов опухолевых заболеваний крови, таких как острый миелоидный лейкоз (омл)
PE20191711A1 (es) Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer
MX2023014457A (es) Peptidos antigenicos para la prevencion y el tratamiento del cancer.
AR095386A1 (es) Péptidos de kntc2 y vacunas que los contienen
PE20230343A1 (es) Peptidos que estimulan respuestas inmunitarias antitumorales
PE20250413A1 (es) Peptidos y combinacion de peptidos novedosos para su uso en inmunoterapia contra diversos tumores
PE20191617A1 (es) Peptidos y combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cancer
PH12014500720A1 (en) Topk peptides and vaccines including the same